Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qingdao Haier Biomedical Co's quarterly Total Liabilities
increased
from Sep. 2025 (¥1,065.07 Mil) to Dec. 2025 (¥1,168.32 Mil) but then
declined
from Dec. 2025 (¥1,168.32 Mil) to Mar. 2026 (¥1,153.63 Mil).
Qingdao Haier Biomedical Co's annual Total Liabilities
increased
from Dec. 2023 (¥1,085.72 Mil) to Dec. 2024 (¥1,169.33 Mil) but then
declined
from Dec. 2024 (¥1,169.33 Mil) to Dec. 2025 (¥1,168.32 Mil).
Qingdao Haier Biomedical Co Total Liabilities Related Terms
Qingdao Haier Biomedical Co Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao Haier Biomedical Co Total Liabilities Chart
Qingdao Haier Biomedical Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Qingdao Haier Biomedical Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao Haier Biomedical Co (SHSE:688139) has a Total Liabilities of ¥1,154 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Qingdao Haier Biomedical Co and its competitors.
Is Qingdao Haier Biomedical Co's Total Liabilities too high?
Qingdao Haier Biomedical Co's current Total Liabilities is ¥1,154 Mil. Overall, Qingdao Haier Biomedical Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qingdao Haier Biomedical Co's Total Liabilities compare to ABT and SYK?
Qingdao Haier Biomedical Co's Total Liabilities of ¥1,154 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Qingdao Haier Biomedical Co and its competitors. Qingdao Haier Biomedical Co's current Total Liabilities is ¥1,154 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qingdao Haier Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co (SHSE:688139) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥36.05, compared to a current price of ¥28.18 — trading 21.8% below its estimated fair value. The current Total Liabilities is ¥1,154 Mil. Qingdao Haier Biomedical Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Qingdao Haier Biomedical Co (SHSE:688139), the current Total Liabilities is ¥1,154 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qingdao Haier Biomedical Co (SHSE:688139) Overvalued in 2026?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co stock appears to be undervalued.
The current stock price of ¥28.18 is trading 21.8% below its estimated GF Value™ of ¥36.05.
GuruFocus considers Qingdao Haier Biomedical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688139:
Total Liabilities: ¥1,154 Mil
GF Value™: ¥36.05 vs. price of ¥28.18 (21.8% below fair value)
No single metric tells the full story. See the SHSE:688139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
84GF Score
Get the complete analysis for SHSE:688139
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688139 has been successfully added to your 
